Aton SA operates as a biopharmaceutical company which engages in the research and development of targets and therapies for the treatment of proliferative diseases. It develops inecalcitol for the treatment of prostate cancer, acute and chronic lymphocytic leukemia, and acute and chronic myeloid leukemia. The company was founded by Arthur Donny Strosberg on December 29, 1997 and is headquartered in Paris, France.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company